Palabras clave
paciente asintomático
daño renal
nefroprotección
alopurinol
febuxostat
Cómo citar
Resumen
Contexto: el ácido úrico es el producto final de la degradación de las purinas en los primates, en condiciones normales es un agente antioxidante endógeno y participa en varias vías fisiológicas, sin embargo, cuando los niveles séricos de urato se incrementan, estos participan en el desarrollo de diversas enfermedades.
Desde el siglo XIX se conoce de la asociación entre hiperuricemia y daño renal, aunque ninguna guía de manejo recomienda el uso de fármacos hipouricemiantes en pacientes asintomáticos, en algunos casos especiales, el manejo farmacológico beneficiará a pacientes con hiperuricemia, brindando protección al riñón y disminuyendo el riesgo de desarrollar enfermedad renal terminal.
Objetivo: describir la relación entre hiperuricemia y daño renal, y analizar los casos en los que el manejo de esta condición con medicamentos resultará en un beneficio para el riñón de los pacientes.
Metodología: revisión de la literatura sobre la participación de la hiperuricemia en el daño renal y análisis de los artículos revisados.
Resultados: el manejo de la hiperuricemia asintomática puede proteger el riñón en algunas situaciones específicas.
Conclusiones: hay situaciones específicas para la disminución de los niveles séricos de ácido úrico.
Citas
Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016;15(213):8-14. https://doi.org/10.1016/j.ijcard.2015.08.109
Sánchez-Lozada LG, Rodríguez-Iturbe B, Kelley EE, Nakagawa T, Madero M, Feig DI, et al. Uric Acid and Hypertension: An Update with Recommendations. Am J Hypertens. 2020;33:583-594. https://doi.org/10.1093/ajh/hpaa044
Méndez Landa CE. Renal Effects of Hyperuricemia. Contrib Nephrol. 2018;192:8-16. https://doi.org/10.1159/000484273
Guerrero-García C, Rubio-Guerra AF. Hiperuricemia y síndrome metabólico. En Castro-Martínez MG, Rubio Guerra AF, editores. Diabetes y corazón. México: Editorial Alfil; 2021. p. 207-216.
Paul B, Anoopkumar K, Krishnan V. Asymptomatic hyperuricemia: is it time to intervene? Clin Rheumatol. 2017;36:2637-2644. https://doi.org/10.1007/s10067-017-3851-y
Rubio-Guerra AF, Morales-López H, Garro-Almendaro AK, et al. Circulating levels of uric acid and risk for metabolic syndrome. Curr Diabetes Rev. 2017;13:87-90. https://doi.org/10.2174/1573399812666150930122507
Sánchez-Lozada LG. The Pathophysiology of Uric Acid on Renal Diseases. Contrib Nephrol. 2018;192:17-24. https://doi.org/10.1159/000484274
Goldberg A, García-Arroyo F, Sasai F, Rodríguez-Iturbe B, Sánchez-Lozada LG, Lanaspa MA, et al. Mini Review: Reappraisal of Uric Acid in Chronic Kidney Disease. Am J Nephrol. 2021;52:837-844. https://doi.org/10.1159/000519491
Ejaz AA, Nakagawa T, Kanbay M, Kuwabara M, Kumar A, García Arroyo FE, et al. Hyperuricemia in Kidney Disease: A Major Risk Factor for Cardiovascular Events, Vascular Calcification, and Renal Damage. Semin Nephrol. 2020;40:574-585. https://doi.org/10.1016/j.semnephrol.2020.12.004
Stack AG, Johnson ME, Blak B, Klein A, Carpenter L, Morlock R, et al. Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort study. BMJ Open. 2019;9:e031550. https://doi.org/10.1136/bmjopen-2019-031550
Chou YC, Kuan JC, Yang T, Chou W, Hsieh P, Bai C, et al. Elevated uric acid level as a significant predictor of chronic kidney disease: a cohort study with repeated measurements. J Nephrol. 2015;28:457-462. https://doi.org/10.1007/s40620-014-0158-9
Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19:2407-2413. https://doi.org/10.1681/ASN.2008010080
Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein J, Lurbe E, Mancia G, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1-11. https://doi.org/10.1016/j.ejim.2020.07.006
Sharaf El Din UA, Salem MM, Abdulazim DO. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review. J Adv Res 2017;8: 537-548. https://doi.org/10.1016/j.jare.2016.11.004
Ejaz AA, Johnson RJ, Shimada M, Mohandas R, Alquadan KF, Beaver TM, et al. The Role of Uric Acid in Acute Kidney Injury. Nephron. 2019;142:275-283. https://doi.org/10.1159/000499939
Brucato A, Cianci F, Carnovale C. Management of hyperuricemia in asymptomatic patients: A critical appraisal. Eur J Intern Med. 2020;74:8-17. https://doi.org/10.1016/j.ejim.2020.01.001
Høieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux R, Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65:1041-1049. https://doi.org/10.1111/j.1523-1755.2004.00484.x
Cipolletta E, Tata LJ, Nakafero G, Avery AJ, Mamas MA, Abhishek A. Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients With Gout. JAMA. 2022;328:440-450. https://doi.org/10.1001/jama.2022.11390
Rubio-Guerra AF, Narváez-Rivera JL, Benítez-Maldonado DR, Guerrero-García C, Arana-Pazos KC, Vargas-Ayala G. Correlación entre niveles de ácido úrico y velocidad de la onda del pulso en sujetos con síndrome metabólico . Nefro Latinoam 2019;16:33-38. https://doi.org/10.24875/NEFRO.19000058
Chalès G. How should we manage asymptomatic hyperuricemia? Joint Bone Spine. 2019;86(4):437-443. https://doi.org/10.1016/j.jbspin.2018.10.004
Sato Y, Feig DI, Stack AG, Kang D, Lanaspa M, Ejaz A, et al. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat Rev Nephrol. 2019;15:767-775. https://doi.org/10.1038/s41581-019-0174-z
Johnson RJ, Bakris GL, Borghi C, Chonchol M, Feldman D, Lanaspa M, et al. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. Am J Kidney Dis. 2018;71:851-865. https://doi.org/10.1053/j.ajkd.2017.12.009
Vargas-Santos AB, Peloquin CE, Zhang Y, Neogi T. Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment. JAMA Intern Med. 2018;178:1526-1533. https://doi.org/10.1001/jamainternmed.2018.4463
Kohagura K, Tana T, Higa A, Yamazato M, Ishida A, Nagahama K, et al. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia. Hypertens Res. 2016;39:593-597. https://doi.org/10.1038/hr.2016.37
Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, et al. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis. 2015;65:543-549. https://doi.org/10.1053/j.ajkd.2014.11.016
Eleftheriadis T, Golphinopoulos S, Pissas G, Stefanidis I. Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial. J Adv Res. 2017;8:555-560. https://doi.org/10.1016/j.jare.2017.05.001
Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, et al. Effects of Allopurinol on the Progression of Chronic Kidney Disease. N Engl J Med. 2020;382:2504-2513. https://doi.org/10.1056/NEJMoa1915833
Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51-59. https://doi.org/10.1053/j.ajkd.2005.10.006
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 jul. 28;375:323-34. https://doi.org/10.1056/NEJMoa1515920
Kao MP, Ang DS, Gandy SJ, et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2011;22:1382-1389. https://doi.org/10.1681/ASN.2010111185
Terawaki H, Nakayama M, Miyazawa E, Murata Y, Nakayama K, Matsushima M, et al. Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients: the Gonryo study. Clin Exp Nephrol. 2013;17:549-553. https://doi.org/10.1007/s10157-012-0742-z
Ghang BZ, Lee JS, Choi J, Kim J, Yoo B. Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial. RMD Open. 2022;8:e001944. https://doi.org/10.1136/rmdopen-2021-001944
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.